IPO Year: 2022
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/20/2024 | $10.00 | Buy | H.C. Wainwright |
5/16/2024 | $10.00 | Neutral → Buy | Citigroup |
4/22/2024 | $17.00 | Buy | Chardan Capital Markets |
4/8/2024 | Buy | TD Cowen | |
4/3/2024 | $12.00 | Outperform | Wedbush |
1/16/2024 | $18.00 → $9.00 | Buy → Hold | Stifel |
12/8/2023 | $10.00 | Neutral | Citigroup |
10/9/2023 | $19.00 | Outperform | BMO Capital Markets |
7/31/2023 | $24.00 | Buy | Guggenheim |
4/18/2023 | $18.00 | Buy | Stifel |
-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of lead Prime Editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile -- -- Received U.S. FDA Rare Pediatric Drug designation for PM359 for CGD; initiated IND-enabling studies and remain on track to file IND application in 2024 -- -- Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine's third patent, No. 11,795,452 --
-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio's shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing -- -- Cash, cash equivalents, investments and restricted cash balance of $221.1 million as of June 30, 2023 -- CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
H.C. Wainwright initiated coverage of Prime Medicine with a rating of Buy and set a new price target of $10.00
Citigroup upgraded Prime Medicine from Neutral to Buy and set a new price target of $10.00
Chardan Capital Markets initiated coverage of Prime Medicine with a rating of Buy and set a new price target of $17.00
TD Cowen initiated coverage of Prime Medicine with a rating of Buy
Wedbush initiated coverage of Prime Medicine with a rating of Outperform and set a new price target of $12.00
Stifel downgraded Prime Medicine from Buy to Hold and set a new price target of $9.00 from $18.00 previously
Citigroup initiated coverage of Prime Medicine with a rating of Neutral and set a new price target of $10.00
BMO Capital Markets initiated coverage of Prime Medicine with a rating of Outperform and set a new price target of $19.00
Guggenheim initiated coverage of Prime Medicine with a rating of Buy and set a new price target of $24.00
Stifel initiated coverage of Prime Medicine with a rating of Buy and set a new price target of $18.00
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company's Chief Financial Officer, effective January 17, 2024. A seasoned financial executive with over twenty years' experience in the biotechnology industry, Dr. Reine will be responsible for the company's financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company. "I am delighted to welcome Allan to Prime Medicine. He brings tremendou
-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE platform to multiplex edit CAR-T cells to be presented at ASGCT Annual Meeting -- -- Expanded Board of Directors with appointment of Jeff Marrazzo, former CEO of Spark Therapeutics -- -- Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine's second patent, No. 11,643,652, and allowed third patent application, No. 17/751,599 -- -- Cash, cash equivalents, investments and restricted cash balance of $263.0 million as of March 31, 2023 -- CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME)
SC 13G/A - Prime Medicine, Inc. (0001894562) (Subject)
SC 13D - Prime Medicine, Inc. (0001894562) (Subject)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
10-Q - Prime Medicine, Inc. (0001894562) (Filer)
8-K - Prime Medicine, Inc. (0001894562) (Filer)
8-K - Prime Medicine, Inc. (0001894562) (Filer)
DEFA14A - Prime Medicine, Inc. (0001894562) (Filer)
8-K - Prime Medicine, Inc. (0001894562) (Filer)
10-Q - Prime Medicine, Inc. (0001894562) (Filer)
8-K - Prime Medicine, Inc. (0001894562) (Filer)
ARS - Prime Medicine, Inc. (0001894562) (Filer)
DEFA14A - Prime Medicine, Inc. (0001894562) (Filer)
DEF 14A - Prime Medicine, Inc. (0001894562) (Filer)
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Wednesday, September 4, 2024, at 1:05 p.m. ET in New York, NY.Wells Fargo Healthcare Conference: Fireside chat on Thursday, September 5, 2024, at 11:00 a.m. ET in Boston, MA.Cantor Global Healthcare Conference: Company management will host 1x1 investor meetings on Tuesday, September 17, 2024, in New York, NY.Chardan's 8t
CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. "In the second quarter, we achieved a key milestone for Prime Medicine and our next-generation gene editing technology, securing clearance from the U.S. Food and Drug Administration (FDA) to advance PM359, our Prime Editor for the treatment of chronic granulomatous disease (CGD), into the clinic. We are now in the process of initiating our Phase 1/2 clinical trial, and we look for
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer will present at two upcoming investor conferences: Jefferies Healthcare Conference: Fireside chat on Wednesday, June 5, 2024, at 1:30 p.m. ET in New York, NY.Goldman Sachs 45th Annual Global Healthcare Conference: Fireside chat on Monday, June 10, 2024, at 2:00 p.m. ET in Miami Beach, FL. Live audio webcasts of both presentations will be available under "Events & Presentations" in the News & Events section
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024, at 4:30 p.m. ET in New York, NY. A live audio webcast of the fireside chat will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website
-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Presented new preclinical data demonstrating broad potential of Prime Editing technology at LNP Formulation and Process Development Summit and ASGCT 2024 -- -- Appointed Tony Coles, M.D. as senior advisor -- CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the first quarter ended March 31, 2024, and provided a
Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of its ex vivo Prime Editing program, PM359, to correct a common disease-causing mutation of chronic granulomatous disease (CGD). The data will be
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a panel discussion at the 27th Annual Milken Institute Global Conference entitled "Things That Will Blow Your Mind." The panel will bring together innovators across multiple disciplines to discuss cutting-edge technologies, inventions, and scientific breakthroughs, and to share a glimpse of what the future will look like. The Conference will take place May 5-8, 2024, i
First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine's Ex Vivo Product Candidate Designed to Correct a Prevalent Disease-Causing Mutation of CGD Initial Data Expected in 2025 CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for PM359, submitted on March 29, for the treatment of chronic granulomatous disease (CGD), enabling the Company to initiate its global Phase 1/2 clinical trial
-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter clinical development in 2024, with initial data expected in 2025 -- -- Prime Medicine Co-Founder, David Liu, Ph.D., Awarded ASGCT Outstanding Achievement Award -- CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that the Company will present preclinical data highlighting the broad potential of its Prime Editing technology an
-- Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 -- -- Progressing broader portfolio across core areas of focus; expect to initiate IND-enabling activities in first liver and ocular disease programs in 2024 -- -- Advancing hotspot and PASSIGE™ Prime Editors for CF following entry into therapeutic development agreement with Cystic Fibrosis Foundation -- -- Completed upsized $161 million public offering -- CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative ge
HC Wainwright & Co. analyst Arthur He initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces Price Target of $10.
Citigroup analyst Samantha Semenkow upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $10 price target.
JP Morgan analyst Eric Joseph maintains Prime Medicine (NASDAQ:PRME) with a Overweight and lowers the price target from $16 to $15.
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.47) by 6.38 percent.
Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trialCAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of its ex vivo Prime Editing program, PM359, to correct a common disease-causing mutation of chronic granulomatous disease (CGD). The data will be prese
Jefferies analyst Maury Raycroft assumes Prime Medicine (NASDAQ:PRME) with a Buy rating and lowers Price Target of $15.
Shares of Aspen Aerogels, Inc. (NYSE:ASPN) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results. Aspen Aerogels posted a GAAP loss of 2 cents per share, compared to market expectations for a loss of 11 cents per share. The company's quarterly sales came in at $94.501 million versus estimates of $75.004 million, according to data from Benzinga Pro. Aspen Aerogels shares jumped 26.2% to $19.21 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Emergent BioSolutions Inc. (NYSE:EBS) gained 72.1% to $3.32 in pre-market trading after the company announced operational changes t
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister its Securities to terminate and suspend its reporting obligations. Clever Leaves Holdings shares dipped 60% to $1.6498 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shares climbed 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash. Collective Audience, Inc. (NASDAQ:CAUD) gained 50.4% to $0.6002 after the company announced a strategic partne
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday's session on reports the company will partner with Baidu for mapping and navigation for Full Self-Driving in China. Tesla shares jumped 10.5% to $185.94 on Monday. Here are some other big stocks recording gains in today's session. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shares surged 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash. ImmunityBio, Inc. (NASDAQ:IBRX) shares rose 36.3% to $10.02. ImmunityBio shares jumped around 44% on Friday after the company annou